Moore KH - Search Results

1

The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2.

Rosenthal NS, Hank JA, Kohler PC, Minkoff DZ, Moore KH, Bechhofer R, Hong R, Storer B, Sondel PM. Rosenthal NS, et al. Among authors: moore kh. J Biol Response Mod. 1988 Apr;7(2):123-39. J Biol Response Mod. 1988. PMID: 3258904

2

Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma.

Sosman JA, Hank JA, Moore KH, Borchert A, Schell K, Kohler PC, Goldstein D, Bechhofer R, Storer B, Albertini MR, et al. Sosman JA, et al. Among authors: moore kh. Cancer Invest. 1991;9(1):35-48. doi: 10.3109/07357909109032798. Cancer Invest. 1991. PMID: 2012995 Review.

3

Phase 1 clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion.

Kohler PC, Hank JA, Moore KH, Storer B, Bechhofer R, Hong R, Sondel PM. Kohler PC, et al. Among authors: moore kh. Cancer Invest. 1989;7(3):213-23. doi: 10.3109/07357908909039840. Cancer Invest. 1989. PMID: 2790538 Clinical Trial.

4

Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.

Goldstein D, Sosman JA, Hank JA, Weil-Hillman G, Moore KH, Borchert A, Bechhofer R, Storer B, Kohler PC, Levitt D, et al. Goldstein D, et al. Among authors: moore kh. Cancer Res. 1989 Dec 1;49(23):6832-9. Cancer Res. 1989. PMID: 2819723

5

Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.

Sosman JA, Kohler PC, Hank J, Moore KH, Bechhofer R, Storer B, Sondel PM. Sosman JA, et al. Among authors: moore kh. J Natl Cancer Inst. 1988 Mar 2;80(1):60-3. doi: 10.1093/jnci/80.1.60. J Natl Cancer Inst. 1988. PMID: 3257526

6

In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.

Hank JA, Kohler PC, Weil-Hillman G, Rosenthal N, Moore KH, Storer B, Minkoff D, Bradshaw J, Bechhofer R, Sondel PM. Hank JA, et al. Among authors: moore kh. Cancer Res. 1988 Apr 1;48(7):1965-71. Cancer Res. 1988. PMID: 3258180

7

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

Sondel PM, Kohler PC, Hank JA, Moore KH, Rosenthal NS, Sosman JA, Bechhofer R, Storer B. Sondel PM, et al. Among authors: moore kh. Cancer Res. 1988 May 1;48(9):2561-7. Cancer Res. 1988. PMID: 3258545

8

Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin.

Sosman JA, Kohler PC, Hank JA, Moore KH, Bechhofer R, Storer B, Sondel PM. Sosman JA, et al. Among authors: moore kh. J Natl Cancer Inst. 1988 Nov 16;80(18):1451-61. doi: 10.1093/jnci/80.18.1451. J Natl Cancer Inst. 1988. PMID: 3263508 Clinical Trial.

9

Phase 1 clinical evaluation of recombinant interleukin-2.

Kohler PC, Hank JA, Moore KH, Storer B, Bechhofer R, Sondel PM. Kohler PC, et al. Among authors: moore kh. Prog Clin Biol Res. 1987;244:161-72. Prog Clin Biol Res. 1987. PMID: 3498945

10

Clinical testing of IL-2: in vivo administration of IL-2 induces IL-2 dependent non-MHC-restricted cytotoxicity (NRC).

Sondel PM, Hank JA, Rosenthal N, Moore KH, Hong R, Storer B, Kohler PC. Sondel PM, et al. Among authors: moore kh. Prog Clin Biol Res. 1987;244:173-84. Prog Clin Biol Res. 1987. PMID: 3498947 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

221 results

Search Page

Filters